Pharma brands have long been among the biggest investors in TV advertising. But the landscape has shifted dramatically. Linear TV viewership has declined while ad-supported streaming has exploded, pushing connected TV to the center of many healthcare media plans. As more advertisers run campaigns across both linear and CTV, a critical problem has emerged: how do you measure reach and frequency across two fundamentally different environments?
ACR data is what makes that measurement possible. It is the missing ingredient connecting linear TV exposure to digital campaign performance, and it is increasingly shaping how pharma marketers plan, optimize, and prove the value of their TV investments.
What Is ACR Data?
ACR stands for automatic content recognition, a technology built into smart TVs that identifies exactly what content a viewer is watching, including both live linear programming and streaming apps. The TV's built-in ACR software captures what appears on screen and matches it against a reference database to log what was viewed, when, and how often.
Before ACR, researchers relied on small panels and viewer surveys to estimate TV ad exposure. Those methods provided a rough approximation, but they lacked the granularity marketers needed to make precise decisions. ACR data changed that entirely. Today, marketers can know the exact frequency at which a household was exposed to an ad, which channels and apps it ran on, and how that exposure maps to real-world outcomes like prescription behavior.
For pharma specifically, ACR data can be matched on a one-to-one basis to anonymized claims data. That link is what allows marketing scientists to evaluate campaign performance across both linear and CTV media buys using a consistent methodology.
How Does ACR Data Technology Work?
When a smart TV with ACR enabled is turned on, the technology continuously samples what is displayed on screen, typically at a rate of several frames per second. Those samples are converted into a digital fingerprint and matched against a vast reference library of TV content and advertisements.
The match is nearly instantaneous and covers everything on the screen regardless of the input source, whether that is a cable or satellite signal, a streaming app, or a broadcast antenna. Because ACR operates at the device level, it captures exposure across all viewing modes on a single TV, giving researchers a complete picture of what that household watched and when.
When combined with a privacy-compliant data onboarding process, ACR signals can be linked to household-level audience data including, in the pharma context, anonymized patient segment information. The result is a measurement framework that spans linear and digital in a single, unified view.
Why Does ACR Data Matter to Pharma Marketers?
A Single View Across Linear and CTV
The most fundamental value of ACR data is de-duplication. Without it, a marketer running campaigns on both linear TV and CTV has no reliable way to know how much their target audience overlaps between the two environments. Some households may be seeing the ad repeatedly on linear while never seeing it on CTV, and vice versa. ACR data closes that gap by providing a single source of truth about household-level ad exposure across both channels.
Reduced Wasted Impressions on Already-Exposed Households
Frequency management is one of the more persistent challenges in TV advertising. Linear buys are purchased at a broad audience level, which means a household that has already seen an ad many times on linear may continue to be served the same creative on CTV simply because the two systems have no visibility into each other. ACR data enables marketers to suppress or cap delivery to households that have already received sufficient linear exposure, reallocating those impressions toward under-reached audiences.
Measurement That Connects to Script Performance
For pharma marketers, campaign success ultimately comes down to outcomes, specifically whether patients are initiating or staying on therapy. ACR data enables that connection by allowing TV ad exposure to be matched against anonymized prescription claims at the household level. Marketers can assess whether exposed households showed higher rates of new-to-brand scripts or therapy adherence compared to unexposed controls, applying the same measurement logic used for digital campaigns to the TV portion of the plan.
In a recent analysis of ACR data across three pharma campaigns run on the DeepIntent platform, CTV delivered up to four times the audience quality of linear TV and converted at a rate of up to five times that of linear.
Optimized Spend Across Both Channels
When linear and CTV are measured using the same methodology, spend allocation becomes a data-driven decision rather than a planning assumption. Marketers can identify which channel is delivering better audience quality and script performance for a given campaign, then shift dollars accordingly. This kind of in-flight optimization was previously impossible for the TV portion of a media plan. ACR data makes it a standard part of campaign management.
Informed Future Campaign Planning With Real Exposure Data
The value of ACR data compounds over time. Each campaign generates a cleaner picture of which linear networks, dayparts, and CTV apps actually reached the target patient population, and at what frequency. That exposure data becomes the foundation for more precise planning on the next campaign, reducing waste from the outset.
How ACR Data Works for Smarter CTV Media Buying
ACR data is most powerful when it is integrated directly into the campaign activation and optimization workflow. At DeepIntent, ACR data feeds into the same platform used to build clinical audience segments, activate CTV inventory, and measure script outcomes. That integration means the insights from linear TV exposure are available in real time to inform how CTV delivery is managed.
In practice, this looks like CTV campaigns that are automatically adjusted based on linear exposure signals: reaching households that linear missed, capping frequency for households that linear already saturated, and continuously refining audience targeting based on which segments are converting at the highest rate.
For pharma marketers navigating a TV landscape split across linear, streaming, and digital, that closed loop between measurement and activation is where ACR data delivers its clearest advantage.
To learn more about how ACR data can improve the reach, frequency, and clinical impact of your TV campaigns, explore DeepIntent's connected TV capabilities or speak with our team.
